Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial

Overview of attention for article published in BMC Medicine, October 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 22 Dimensions

Readers on

mendeley: 23 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 1 X users, with an upper bound of 906 followers.

New article: Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial https://t.co/f44ZJ6kWkk #gastriccancer #oncology https://t.co/HDZV8Ls9U2

Reply Repost Favourite

New article: Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial https://t.co/Vbqmr3MxBz #pancreaticcancer #oncology https://t.co/s77AsSIUA5

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.